24/04/20: BARD1 Life Sciences Limited was represented at the AACR Annual Meeting 2020 by CSO Dr Irmgard Irminger-Finger who gave an invited oral presentation on 24 April 2020.

Title: A BARD1 autoimmune antibodies test for early detection of ovarian cancer.
Session Title: Translational Prevention Studies
The American Association of Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.
The AACR held its Annual Meeting 2020 under the leitmotif Turning Science into Lifesaving Care
The AACR Annual Meeting 2020 was scheduled for 24-29 April 2020 in San Diego, California, but was held as the AACR Virtual Annual Meeting 2020.

23/10/18    Article published by SmallCaps today BARD1 develops world first blood test for breast cancer detection

23/10/18    Proactive Investors covers BD1s breast cancer test announcement today BARD1 Life Sciences develops world’s first blood test for early detection of breast cancer

21/5/18    Article published by finfeed BARD1 Life Sciences inks critical deal to develop autoantibody test

21/5/18    Article published by StocksDigital in nextBIOTECH Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

18/5/18    Article published by Proactive Investors BARD1 Life Sciences signs agreement to develop custom research assay

18/5/18    Interview of BARD1 CEO Dr Leearne Hinch by Proactive Investors BARD1 Life Sciences approaching “important milestone” on path to commercialisation

9/1/18     Article published by SMALL CAPS on BARD1’s Ovarian Cancer Detection Study https://smallcaps.com.au/bard1-success-non-invasive-ovarian-cancer-detection-study/

2/1/17     Interview of BARD1 LSL Executive Director and CSO Dr Irmgard Irminger-Finger by Startwerk “BARD1AG SA: The real fight against lung cancer” https://www.startwerk.ch/2017/01/31/bard1ag-sa-the-real-fight-against-lung-cancer/

5/12/16     BARD1 Life Sciences Limited (ASX:BD1) advises that it has relocated its headquarters to the Harry Perkins Institute of Medical Research (the Perkins) at QEII Medical Centre in Nedlands, Western Australia. The Perkins houses world-class research teams, latest equipment and state-of-the-art facilities that will enable BARD1 to collaborate with Perkins’ researchers to expand its research programs in cancer diagnostics and therapeutics. BARD1’s Registered Office remains unchanged at the Subiaco address.

14/11/16     Presentation by CSO Dr Irminger-Finger at the 1st International Caparica Conference in  Splicing (12th-14th September 2016 | Caparica | Lisbon | Portugal)